AAV-Mediated CAR-T Engineering for Persistence and Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies face challenges such as antigen loss, metabolic suppression, insufficient T cell trafficking, and severe toxicity, leading to poor persistence and efficacy in treating solid tumors and relapsed liquid cancers.
Innovation Solution
The development of a platform for massively parallel CAR-T engineering using AAV vectors with crRNA and CAR expression cassettes, allowing for targeted knock-in and knockout of genes to enhance persistence and cytotoxic activity, and reduce exhaustion, through the use of RNA-guided endonucleases like Cas12a/Cpf1 for efficient generation and selection of CAR-T variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If traditional CAR-T cell therapy is used, then initial anti-tumor activity is achieved, but persistence and long-term efficacy are poor due to antigen loss, metabolic suppression, and T cell exhaustion
Solution Approach 1:
The patent segments the CAR-T cell engineering process into multiple independent modules: (1) CRISPR-Cas9 based gene knockout modules to eliminate exhaustion markers and metabolic suppression pathways, (2) CAR expression modules with optimized signaling domains, and (3) selection marker modules. This modular segmentation allows systematic optimization of each function independently while maintaining overall cell persistence and efficacy.
Solution Approach 2:
The patent applies parameter changes by systematically varying multiple genetic parameters simultaneously: knocking out exhaustion markers (PD-1, TIM-3, LAG-3), metabolic regulators (MYC, HIF-1α), and co-inhibitory receptors, while introducing enhanced CAR constructs with modified signaling domains. This multi-parameter optimization transforms CAR-T cells from transient effectors to persistent, reliable therapeutic agents.
2Reliability
If CAR-T cells are engineered to enhance persistence and cytotoxic activity, then therapeutic efficacy improves, but manufacturing complexity and time increase
Solution Approach 1:
The patent merges multiple gene editing operations into a single synchronized process. The CRISPR-Cas9 system delivers multiple guide RNAs and cargo DNA simultaneously, enabling concurrent knockout of multiple exhaustion markers and metabolic regulators in one transfection event. This merging reduces manufacturing steps from multiple sequential transfections to a single integrated process.
Solution Approach 2:
The patent implements preliminary action through pre-designed CRISPR guide RNA libraries and optimized cargo DNA constructs that are prepared beforehand. The selection marker systems are pre-configured to automatically identify successfully edited cells, eliminating the need for complex post-editing screening processes and simplifying quality control.
3Reliability
If multiple genes are knocked out to reduce exhaustion and enhance function, then CAR-T cell performance improves, but off-target effects and safety risks increase
Solution Approach 1:
The patent implements feedback mechanisms through dual-selection marker systems that provide real-time verification of correct gene editing. The first selection marker confirms successful CRISPR integration, while the second confirms proper knockout of target genes. This feedback loop ensures only correctly edited cells proceed to expansion, minimizing off-target effects while maintaining high functional reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the creation of CAR-T cells with improved persistence, memory-like surface markers, and cytotoxic cytokine release, translating to enhanced therapeutic efficacy in cancer treatment by optimizing CAR-T cell function and reducing immune exhaustion.
Implementation Method 1
AAV vectors with crRNA and CAR expression cassettes, allowing for targeted knock-in and knockout of genes
Implementation Method 2
the use of RNA-guided endonucleases like Cas12a/Cpf1 for efficient generation and selection of CAR-T variants
Implementation Method 3
compositions and methods for cellular genomic engineering (e.g., T cell engineering) that permit simple and efficient targeted knock-in
Data Source
AI summary
Compositions and methods for cellular genome engineering that permit simple and efficient targeted knock-in of a CAR and simultaneous knockout of individual genes are described. The compositions and methods are especially applicable to massively parallel engineering, selection, and identification of CAR T cell variants exhibiting a desired phenotype. AAV vectors containing crRNA and CAR expression cassettes and homology arms for targeted genomic integration thereof are provided. Also provided are libraries containing a plurality of AAV vectors and methods of use thereof in screens for identifying desirable CAR T cell variants. Methods of treatment using CAR T cell variants exhibiting improvements in one or more phenotypes are also provided.